Watch ALLO. Know when insiders buy.
One email the day a filing lands. Free.
ALLO
Allogene Therapeutics, Inc.
1.33
−0.00 −0.38%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · insiders 47, shorts 49
Insiders, 90 days
−$63K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $457.8MP/E —DIV YIELD —FCF YIELD -22.41%REV TTM —NET INCOME −$165.5MNET CASH —52W 1.05 – 3.06SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $4.6M | — | — | −$46.9M | −$42.7M | — | -0.13 | −$32M | $150K | −$32.1M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$46.1M | −$42.6M | — | -0.18 | −$12.9M | $9K | −$12.9M | Aug 12 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$42.4M | −$38.8M | — | -0.17 | −$27.6M | $0 | −$27.6M | Mar 12 |
| Q3 2025 · Sep 30 | $0 | — | — | −$44.9M | −$41.4M | — | -0.19 | −$29.7M | $243K | −$29.9M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$56.8M | −$50.9M | — | -0.23 | −$39M | $44K | −$39.1M | Aug 12 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$65.2M | −$59.7M | — | -0.28 | −$52.9M | $99K | −$53M | Aug 12 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$60.5M | −$59.9M | — | -0.28 | −$36.7M | $257K | −$37M | Mar 12 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$71.8M | −$66.3M | — | -0.32 | −$44.1M | $429K | −$44.5M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$71.4M | −$66.4M | — | -0.35 | −$63.6M | $0 | −$63.6M | Nov 6 |
| Q1 2024 · Mar 31 | $22K | — | — | −$69.5M | −$65M | — | -0.38 | −$55.9M | $8K | −$55.9M | Nov 6 |
| Q4 2023 · Dec 31derived | $21K | — | — | −$85.1M | −$85.8M | — | -0.51 | −$53.7M | $181K | −$53.9M | Mar 13 |
| Q3 2023 · Sep 30 | $22K | — | — | −$63M | −$62.3M | — | -0.37 | −$55.5M | $12K | −$55.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$209.3M | −$190.9M | — | -0.87 | −$149.2M | $386K | −$149.6M | — | — |
| FY2024 · to Dec 31 | $22K | — | −$273.2M | −$257.6M | -1170863.6% | -1.32 | −$200.3M | $694K | −$201M | — | — |
| FY2023 · to Dec 31 | $95K | — | −$327.7M | −$327.3M | -344489.5% | -2.09 | −$237.7M | $1.5M | −$239.2M | — | — |
| FY2022 · to Dec 31 | $156K | — | −$335.5M | −$340.4M | -218214.1% | -2.38 | −$220.5M | $5.2M | −$225.7M | — | — |
| FY2021 · to Dec 31 | $114.1M | — | −$180.2M | −$182.1M | -159.6% | -1.34 | −$184.8M | $21.4M | −$206.3M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$258.2M | −$316.4M | — | -2.63 | −$115.1M | $66M | −$181.1M | — | — |
Every number comes from Allogene Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.